Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response

Mahmoud A. Khattab1 · Yehia Zakaria1 · Eslam Sadek1 · Aliaa S. Abd EL Fatah1 · Magdy Fouad2 · Muhammed Khattab3 · Hend M. Moness4 · Nashwa Mohamed Adel5 · Elham Ahmed1

Received: 1 July 2021 / Accepted: 4 January 2022 / Published online: 23 January 2022 © The Author(s) 2022

Abstract
It is unclear whether direct-acting antiviral drugs (DAAs) result in the complete eradication of HCV infection or whether some quantities of the virus may persist after achieving a sustained virologic response (SVR). Aim The aim of this work was to study the possibility of the persistence of HCV RNA in peripheral blood mononuclear cells (PBMCs) after achieving SVR following DAA treatment. This study included 100 patients infected with HCV genotype 4, who were candidates for receiving DAAs and who achieved SVR during follow-up, as determined at 12 and/or 24 weeks following the end of treatment. All patients were subjected to demographic, biochemical and hematological assessments. Detection of HCV RNA in the serum and PBMCs and determination of the HCV genotype were performed with real-time PCR. We detected HCV RNA in the PBMCs of 20 out of 100 (20%) patients infected with HCV genotype 4, who achieved SVR. However, the persistent viral load in the PBMCs was very low (range: 400–900 U/mL; mean ± SD: 645.45 ± 153 U/mL). Multiple logistic regression analysis showed that only the higher posttreatment levels of aspartate transaminase (AST) were significantly predictive of HCV RNA persistence in the PBMCs (OR: 1.29; 95% CI: 1.08–1.55). Additionally, according to the Cox proportional hazard model, liver cirrhosis was the only significant risk factor for the persistence of HCV infection in PBMCs (HR: 5.8; 95% CI: 1.3–26.1; P < 0.02). Our results indicated the persistence of HCV RNA in some HCV patients who achieved SVR after treatment with DAAs.

Keywords Occult hepatitis C infection · Mononuclear cells

Introduction
Occult hepatitis C virus infection (OCI) is characterized by the presence of HCV RNA in the liver cells and/or the peripheral blood mononuclear cells (PBMCs) of patients whose serum samples test negative for HCV RNA [1]. In recent years, the treatment options for hepatitis C virus infection have been revolutionized by the development and use of IFN-free oral direct-acting antiviral agents (DAAs) for the treatment of HCV infection. These DAAs, which target the nonstructural viral proteins, have achieved eradication of the virus at a rate approaching 100% regardless of liver fibrosis, prior response to IFN/RBV, sex, age and race [2]. However, it is unclear whether the current antiviral treatment for chronic hepatitis C virus (HCV) infection with direct-acting antiviral agents (DAAs) results in the complete elimination of the virus or whether small quantities of the virus may persist. Although HCV is a hepatotropic virus,
there is ample evidence to suggest that it can also replicate in peripheral blood mononuclear cells (PBMCs), and the infected cells have been reported to contain the negative strand of the HCV RNA, which is the viral replicative intermediate [3]. It has been suggested that HCV, by infecting the PBMCs, can use them as a reservoir that may contribute to the development of resistance to treatment, relapse and the possible occurrence of complications even after clearing of the HCV RNA from the serum of infected patients [4]. On the other hand, HCV-RNA persistence in PBMC in certain patients who achieved HCV RNA clearance is associated with persistent histological abnormality [5]. SVR after DAA treatment may need dual testing in both serum and PBMCs [6].

This study aimed to investigate the possible existence of OCI following SVR after DAA treatment.

Patients and methods

In this prospective cohort study, the recruited chronically HCV-infected patients attended our Minia University Liver Center and were candidates for receiving DAA treatment from 01/01/2017 to 31/9/2018. The eligibility criteria for receiving DAA therapy were consistent with the protocol approved by the national committee for the control of viral hepatitis in Egypt (NCCVH) [7]. The patients with negative serum HCV-RNA as tested by PCR at 12 and/or 24 weeks after the end of antiviral treatment were diagnosed with sustained virologic response (SVR). Only patients infected with HCV genotype 4 who achieved SVR were included in this study. Selection of the study patients was performed regardless of the state of the liver parenchyma (cirrhotic or not) and previous treatment (experienced or naïve patients). The exclusion criteria included coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), patients with liver malignancies or with suspicious nodules on radiologic examination, previous or current use of immunosuppressive drugs and chronic liver diseases other than HCV infection. All patients signed informed written consent forms before participating in the study. The study protocol was approved by the Institutional Research Board of the Minia Faculty of Medicine in Egypt. The study was conducted in accordance with the ethical guidelines in the 1975 Helsinki declaration.

Methods

In the recruited patients, the diagnosis of cirrhosis was made according to the clinical and sonographic criteria for cirrhosis and was confirmed by FibroScan [8, 9]. The patients were supplied with one of the available treatment regimens, predominantly sofosbuvir/daclatasvir/ribavirin. Consistent with the NCCVH Egyptian protocol, the treatment duration was either 12 or 24 weeks according to the patient’s condition, whether treatment naïve, treatment experienced or cirrhotics. DAC/SOF, SIM/SOF or LED/SOF were used in treatment naïve and treatment experienced for 12 Wk. and DAC/SOF/ RBV for 12 Wk or DAC/SOF for 24 Wk were used in cirrhotics. Demographic data and a history of previous treatment failure with PEGylated interferon or DAAs were recorded. Additionally, a history of any concomitant chronic illness, such as diabetes mellitus and hypertension, was noted. A clinical examination was performed that included measurements of body weight and height, which were used to calculate the body mass index [BMI = Weight (kg)/Height2 (m2)] [10]. Additionally, the waist and hip circumferences were measured and used to calculate the waist-to-hip ratio (WHR) [11]. Laboratory investigations were performed in three stages. First, genotype 4 analysis was performed by real-time PCR using the TaqMan Gene Expression Assays Kit supplied by QIAamp Viral RNA Kit (Qiagen). Second, a complete blood count was performed with an automated cell counter (Sysmex KX-21 N (TAO Medical Incorporation, Japan), and liver and renal function tests were performed with the autoanalyzer Konelab i60 (Thermoelectro, Clinical chemistry automation systems, Finland). The INR was measured by a STAGO COMPACT CT coagulation analyzer (Diamond Diagnostics, USA), and HCV-RNA was detected in the serum by real-time PCR. The viral markers HBsAg and HIV Abs were tested with fully automated Chemiluminescence technology (Cobas E 411-Roche-Roche Diagnostics GmbH Germany). All of these investigations were repeated 3–6 months after the end of treatment. We detected HCV-RNA in the serum by PCR 3 and/or 6 months after the end of antiviral treatment when the patient got the sustained virological response (SVR). Blood samples (5–10 mL) were withdrawn in HCV RG RT-PCR Kit tubes (red cap). Whole blood was separated into plasma and cellular components this was done by centrifuging whole blood for 20 min at 800–1600 g. 200 µL of whole blood cells were transferred to a sterile polypropylene tube for PBMC studies. Then plasma was transferred into another sterile polypropylene tube.

RNA isolation for plasma done by the QIAamp DSP Virus Kit (Cat. No. 61704; Qiagen). RNA was incubated with 1 pmol of an HCV 5NC primer RC21 for 8 min at 70 °C and 5 min at 4 °C. RNA template was then reverse transcribed at 60 °C for 1 h with 7.5 U of ThermoscriptTM Reverse Transcriptase, 20 U of RNase Out, 10 mM DTT, 1 mM deoxyribonucleotide and cDNA buffer (50 mM Tris–acetate pH 8.4, 75 mM potassium acetate, 8 mM magnesium acetate) (GibcoBRL Life Technologies) in a final volume of 10 mL. A denaturation step was performed at 95 °C for 5 min and was followed by a RNaseH treatment with 1 U of E. coli RNaseH (GibcoBRL Life Technologies) at 37 °C for 20 min. The primers RC1 (5’-GTCTAGCCATGGCGTTAGTA-3’)
and RC21 (5'-CTCCCAGGGCAGCTCAGGCAAGC-3') were designed to amplify a 220 bp fragment within the 5' non-coding region of the HCV genome.

Blood samples were drawn to test for HCV RNA in PBMCs. The detection was performed in two steps: 1) extraction of HCV-RNA from PBMCs and 2) detection and amplification of HCV by real-time PCR. In the extraction step, PBMCs were isolated from the peripheral blood of HCV-infected patients by density gradient centrifugation. TRIzol reagent was used to extract the HCV-RNA from the PBMCs. The TRIzol reagent is a ready-to-use reagent designed to isolate high-quality total RNA from cell and tissue samples from humans within one hour. TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate and other proprietary components that facilitate the isolation of a variety of large or small RNA species (TRIZOL TM reagent cat. No. 15596018 supplied by SIGMA) [12]. The extracted samples were then stored in a –80 °C refrigerator prior to the next step. Detection of HCV RNA strands in PBMCs was carried out as described by Lohr et al. [13]. Detection and amplification of HCV were performed using DT-Lite 48 (DNA Technology, Russia). We added 10 μl from the extracted sample. The standard control (from 1–4) was added (10 μl) to separate tubes. Then, each tube was capped and placed in the real-time PCR instrument. We had four standard controls, and their concentrations were as follows: Concentration (1) was (1 ~ 5 × 10^7 IU/mL), Concentration (2) was (1 ~ 5 × 10^6 IU/mL), Concentration (3) was (1 ~ 5 × 10^5 5 IU/mL) and Concentration (4) was (1 ~ 5 × 10^4 IU/mL).

The lower detection limit was 10 IU/ml. According to the positivity or negativity for HCV RNA in the PBMCs after achieving SVR, the studied patients were classified into two groups.

**Biostatistical analysis**

The statistical methods of this study were reviewed by Dr. Amani Mohammed, Minia University. Data are reported as medians and ranges, unless stated otherwise. Statistical analyses were performed with IBM SPSS software version 23 (IBM, New York, USA). The Kolmogorov–Smirnov test for normality was used to differentiate between parametric and nonparametric data. For the analysis of quantitative data, independent sample t tests were used, as appropriate. The chi-square (Χ²) test and Fisher’s exact test were applied to analyze qualitative data. Regression analysis was performed to detect the variables that were significantly associated with the persistence of HCV RNA in PBMCs after SVR. Cox hazard regression analysis was carried out to determine the risk factors associated with the persistence of the virus in PBMCs after achieving SVR. For all tests, the probability (p) was considered nonsignificant if ≥ 0.05 and significant if <0.05.

**Results**

In total, 100 patients with chronic hepatitis C infection and SVR at 3/6 months were included in this study. HCV RNA was detected in the PBMCs of 20 out of the 100 (20%) patients with SVR who participated in the study.

Table 1 presents the demographic and descriptive analysis of the study data. The study patients included 53 (53%) males and 47 (47%) females, with a mean age of 57.5 years (range: 23–75 years). The mean BMI was 29.4 kg/m², with a range from 18.5 to 48.3 kg/m². Our data showed that 35% of our subjects were hypertensive, and 29% were diabetic. The percentage of noncirrhotic patients was 51% versus 49% who had liver cirrhosis; those with liver cirrhosis were further classified according to the Child-Turcotte-Pugh (CTP) classification system, with 81.6% classified as CTP class (A), 16.3% as CTP class (B) and 2% as CTP class (C). The distribution of treatment regimens was as follows: sofosbuvir/daclatasvir/ribavirin regimen (39%), sofosbuvir/daclatasvir (20%), sofosbuvir/ribavirin (20%) and others (21%). Additionally, our data showed that 73% of subjects received a 12-week regimen, while only 27% received treatment for 24 weeks. Among the 100 patients who received the antiviral treatment, 90 (90%) were naïve to treatment, while only 10 patients (10%) had been treated before by interferon/ribavirin and this time we used DAC/SOF, SIM/SOF or LED/SOF for 12 Wk.

Regarding the impact of treatment regimens on the persistence of HCV, there was no significant relationship between the treatment type (regimen) and the positivity for viral RNA in the PBMCs (P = 0.7). Additionally, there was no difference in PBMC HCV RNA positivity between patients who were treated for 12 or 24 weeks (P = 0.3). Both the negative and positive PBMC HCV RNA groups had the same percentages of subjects who had been treated previously (10%); P = 1. At the same time, the pretreatment viral loads were not significantly different between the HCV RNA positive and negative groups (Table 2). We found a significantly lower posttreatment prothrombin concentration (PC %) in the HCV RNA-positive group than in the negative group (mean ± SD = 84.9 ± 16.2 vs. 93 ± 11.2, respectively, with p value = 0.01). Similarly, the International Normalized Ratio (INR) was significantly higher in the positive group than in the negative group (mean ± SD = 1.09 ± 0.14 vs. 1.03 ± 0.07, respectively, with P value = 0.01). Furthermore, both the posttreatment ALT and AST levels were significantly higher in the HCV RNA-positive group than in the negative group (P < 0.0001 for both) (Table 3). The posttreatment CBC and other biochemical profiles were not significantly different.
between the groups. In our study, we followed 20 patients with PBMCs that tested positive for the presence of HCV RNA 24 weeks after treatment; PCR was performed with serum samples obtained from these patients, and it was revealed that only one out of the 20 patients developed overt HCV relapse (Table 4).

Table 5 demonstrates the correlation between the posttreatment variables and the persistence of HCVRNA in the PBMCs; there is a highly significant positive correlation between the posttreatment levels of the liver enzymes ALT and AST and PBMC HCV RNA positivity (ALT had $r = 0.57$ and $P < 0.0001$, while AST had $r = 0.61$ and $P < 0.0001$). At the same time, both the posttreatment prothrombin concentration and the INR were correlated with PBMC HCV RNA positivity ($r = −0.28$ and $P = 0.004$ for PC% and $r = 0.26$ and $P = 0.008$ for INR). Utilizing multiple regression analysis to identify the variables associated with the persistence of the HCV RNA in the PBMCs among the studied subjects, we observed that only the posttreatment liver enzyme AST had a significant predictive ability for the persistence of HCV RNA in the PBMCs (OR: 1.29; 95% CI: 1.08–1.55 and $P = 0.005$; Table 6). Using the Cox proportional hazard model to evaluate the effect of various variables on the persistence of HCV RNA in the PBMCs, we found that only the presence of liver cirrhosis was associated with a significant risk for PBMC HCV RNA positivity (HR: 5.828, 95% CI: 1.3–26.1 with $P = 0.02$). Other factors, such as age, sex and platelet count, liver enzyme levels, treatment type and treatment experience, had no significant effects (Table 7).

Discussion

Our study has shown the existence of OCI among some HCV-infected patients who were treated with the recently available DAAs. Our data indicated persistence of HCV RNA in the PBMCs in 20 out of 100 (20%) patients infected with HCV genotype 4, who achieved SVR after 3/6 months of DAA treatment.

OCI was described by Pham et al. [14] as the presence of HCV RNA in the liver tissue and/or peripheral blood mononuclear cells (PBMC) in patients who tested negative for serum HCV RNA. At a later date, Pham et al. reported
| Variable                  | Group 1 − ve PCR in PBMCs | Group 2 + ve PCR in PBMCs | P value |
|--------------------------|----------------------------|---------------------------|---------|
| Age (years)              |                            |                           |         |
| Range                    | 23–75                      | 32–72                     | 0.8     |
| Mean ± SD                | 57.3 ± 11.4                | 58 ± 10.5                 |         |
| Duration of treatment    |                            |                           |         |
| 3 months                 | 60 (75%)                   | 13 (65%)                  | 0.3     |
| 6 months                 | 20 (25%)                   | 7 (35%)                   |         |
| Previous treatment failure |                          |                           |         |
| Yes                      | 8 (10%)                    | 2 (10%)                   | 1.00    |
| No                       | 72 (90%)                   | 18 (90%)                  |         |
| Type of treatment        |                            |                           |         |
| SOF and DAC              | 17 (21.2%)                 | 3 (15%)                   | 0.7     |
| SOF, IFN and RIB         | 10 (12.5%)                 | 2 (10%)                   |         |
| SOF and LED              | 1 (1.2%)                   | 0 (0%)                    |         |
| SOF and IFN              | 3 (3.8%)                   | 0 (0%)                    |         |
| SOF and RIB              | 13 (16.2%)                 | 7 (35%)                   |         |
| SOF, DAC and RIB         | 31 (38.8%)                 | 8 (40%)                   |         |
| SOF and SIM              | 2 (2.5%)                   | 0 (0%)                    |         |
| SOF, LED and RIB         | 2 (2.5%)                   | 0 (0%)                    |         |
| OMB, PAR and RIT         | 1 (1.2%)                   | 0 (0%)                    |         |
| Hb (g/dl)                |                            |                           |         |
| Range                    | 8–16                       | 9.5–15.5                  | 0.5     |
| Mean ± SD                | 12.4 ± 1.6                 | 12.1 ± 1.7                |         |
| TLC (×10⁹/L)             |                            |                           |         |
| Range                    | 2500–10,400                | 2800–7600                 | 0.04*   |
| Mean ± SD                | 5836.2 ± 1996.3            | 5040 ± 1425.8             |         |
| PCR (IU/mL)              |                            |                           |         |
| Range                    | 1534–13,646,369            | 14,498–7,301,515          | 0.4     |
| Mean ± SD                | 962,010 ± 1,912,916        | 1,306,913 ± 2,084,741     |         |
| Platelet count (10⁹/L)   |                            |                           |         |
| Range                    | 44–432                     | 49–413                    | 0.43    |
| Median                   | 170.5                      | 152                      |         |
| Mean ± SD                | 188.7 ± 87.5               | 174.2 ± 95.1              |         |
| Creatinine (mg/dL)       |                            |                           |         |
| Range                    | 0.5–1.9                    | 0.6–1.8                   | 0.9     |
| Mean ± SD                | 0.88 ± 0.2                 | 0.89 ± 0.3                |         |
| Albumin (g/dL)           |                            |                           |         |
| Range                    | 3–5                        | 3.1–4.5                   | 0.4     |
| Mean ± SD                | 4.1 ± 0.4                  | 4 ± 0.4                   |         |
| Total bilirubin (mg/dL)  |                            |                           |         |
| Range                    | 0.3–3.2                    | 0.3–2.4                   | 0.5     |
| Mean ± SD                | 0.9 ± 0.5                  | 0.8 ± 0.5                 |         |
| ALT (U/L)                |                            |                           |         |
| Range                    | 14–122                     | 25–110                    | 0.002*  |
| Mean ± SD                | 32.1 ± 18.4                | 46.6 ± 18.7               |         |
| AST (U/L)                |                            |                           |         |
| Range                    | 20–88                      | 24–89                     | 0.06    |
| Mean ± SD                | 38.4 ± 13.8                | 45.3 ± 18.3               |         |
that the immune system supports HCV replication regardless of the clinical appearance of infection and although HCV RNA occurs at a comparable frequency in all cell subtypes in CHC, monocytes contain the greatest loads. In contrast, B cells tended to carry the highest virus quantities during occult infection and monocytes appeared to be the least frequently infected [15].

### Table 3

| Posttreatment PBMC PCR (IU/mL) | Group 1 | Group 2 | P value |
|--------------------------------|---------|---------|---------|
| N=80 negative PCR in PBMC | 400–900 | 645.45 ± 153.2 | < 0.001* |
| N=20 positive PCR in PBMC | 6.5–14.9 | 12.5 ± 1.8 | 0.2 |
| Hb (g/dl) | 9.7–17.5 | 12.9 ± 1.4 | 0.7 |
| Platelet count (×10^9/L) | 45–422 | 202 ± 97.7 | 0.05 |
| Range | 65–415 | 193.9 ± 110.8 | 0.05 |
| Mean ± SD | 5840 ± 2030 | 4865 ± 1781 | 0.05 |
| TLC (×10^9/L) | 2.8–11.100 | 56–100 | 0.01* |
| Range | 84.9 ± 16.2 | 1.09 ± 0.14 | 0.01* |
| Mean ± SD | 93 ± 11.2 | 1.03 ± 0.07 | 0.01* |
| INR | 1–1.32 | 1–1.51 | 0.4 |
| Range | 29.4 ± 5 | 29.3 ± 6.5 | 0.4 |
| Mean ± SD | 18.5–42.1 | 20.9–48.3 | 0.4 |
| BMI (kg/m²) | 39.4 ± 5 | 39.8 ± 11.3 | 0.4 |
| Range | 0.9 ± 0.06 | 0.9 ± 0.08 | 0.4 |
| Mean ± SD | 11–80 | 19–330 | 0.0001* |
| ALT (U/L) | 26.1 ± 12.2 | 86.9 ± 75.8 | 0.0001* |
| Range | 39–342 | 96.8 ± 73.6 | 0.0001* |

P value calculated by chi-square test and independent sample t-test

### Table 4

| PBMCs positive for HCV RNA | HCV RNA positive in serum | HCV RNA negative in serum | N:1 patient (%) | N:19 patients (%) |
|----------------------------|---------------------------|---------------------------|----------------|-----------------|
| N:20 patients              | 20 patients               | 19 patients               | 15–83 | 39–342 |
| Mean ± SD | 34.1 ± 13.3 | 96.8 ± 73.6 | 0.0001* |

### Table 5

| POSITIVE PCR in PBMC Spearman’s rho | r | P value |
|-------------------------------------|---|---------|
| Posttreatment platelet count (×10^9/L) | −0.04 | 0.6 |
| Posttreatment HB (g/dl) | −0.03 | 0.7 |
| Posttreatment TLC (×10^9/L) | −0.13 | 0.1 |
| Posttreatment PC% | −0.28 | 0.004* |
| Posttreatment INR | 0.26 | 0.008* |
| Posttreatment ALT (U/L) | 0.57 | 0.0001* |
| Posttreatment AST (U/L) | 0.61 | 0.0001* |

### Table 6

| Independent variables | OR (95% CI) | P value |
|-----------------------|-------------|---------|
| Age (years) | 1.057 (0.91–1.22) | 0.4 |
| Sex | 2.588 (0.63–10.51) | 0.1 |
| BMI (kg/m²) | 1.023 (0.93–1.121) | 0.6 |
| Cirrhosis | 5.828 (1.30–26.1) | 0.02* |
| Previous treatment failure | 0.683 (0.13–3.351) | 0.6 |
| Pretreatment Hb (g/dl) | 0.9 (0.7–1.2) | 0.7 |
| Pretreatment TLC (×10^9/L) | 1 (1–1) | 0.1 |
| Pretreatment platelets (×10^9/L) | 0.9 (0.99–1.006) | 0.7 |
| Pretreatment creatinine (mg/dL) | 1.8 (0.3–10.05) | 0.4 |
| Pretreatment albumin (g/dl) | 0.6 (0.2–2.03) | 0.4 |
| Pretreatment TB (mg/dL) | 0.3 (0.1–1.3) | 0.1 |
| Pretreatment ALT (U/L) | 1.02 (0.9–1.07) | 0.1 |
| Pretreatment AST (U/L) | 0.99 (0.93–1.05) | 0.7 |
| Pretreatment PCR (IU/mL) | 1 (1–1) | 0.1 |

### Table 7

| HR (95% CI) | P value |
|-------------|---------|
| Age (years) | 1.026 (0.97–1.077) | 0.2 |
| Sex | 2.588 (0.63–10.51) | 0.1 |
| BMI (kg/m²) | 1.023 (0.93–1.121) | 0.6 |
| Cirrhosis | 5.828 (1.30–26.1) | 0.02* |
| Previous treatment failure | 0.683 (0.13–3.351) | 0.6 |
| Pretreatment Hb (g/dl) | 0.9 (0.7–1.2) | 0.7 |
| Pretreatment TLC (×10^9/L) | 1 (1–1) | 0.1 |
| Pretreatment platelets (×10^9/L) | 0.9 (0.99–1.006) | 0.7 |
| Pretreatment creatinine (mg/dL) | 1.8 (0.3–10.05) | 0.4 |
| Pretreatment albumin (g/dl) | 0.6 (0.2–2.03) | 0.4 |
| Pretreatment TB (mg/dL) | 0.3 (0.1–1.3) | 0.1 |
| Pretreatment ALT (U/L) | 1.02 (0.9–1.07) | 0.1 |
| Pretreatment AST (U/L) | 0.99 (0.93–1.05) | 0.7 |
| Pretreatment PCR (IU/mL) | 1 (1–1) | 0.1 |
Since its discovery, OCI has been documented in different populations, such as patients with cryptogenic hepatitis, hemodialysis patients, patients with cryoglobulinemia, HCC patients with undetermined etiology and even apparently healthy people [16, 17]. Additionally, there is an increasing amount of data suggesting that HCV relapses may represent activation of an occult hepatitis C virus infection [18]. Indeed, the gold standard for OCI diagnosis is detection of HCV RNA by nucleic acid amplification testing (NAT) from hepatocytes by liver biopsy. However, as liver biopsies are invasive, fairly high threat and are not readily obtainable, alternative diagnostic methods for detecting OCI developed [19]. The HCV-RNA detection rates in liver biopsy specimens varied widely among studies, reaching to 83% [20, 21]. The detection rates of HCV-RNA in PBMCs have varied widely among studies investigating OCI, ranging from 0 to 50% [22–25]. For example, using a less sensitive assay to detect HCV-RNA, Carreno et al. found that 6 out of 12 (50%) individuals had detectable genomic HCV-RNA in PBMCs; the samples were obtained from anti-HCV antibody-positive patients who had normal ALT levels and whose serum had tested negative for HCV RNA for at least 12 months [20].

In contrast, Bernardin et al. [22] using a highly sensitive transcription-mediated amplification (TMA) test performed in duplicate assays, found that none of their 69 aviremic individuals with previous hepatitis C infections had detectable PBMC-associated HCV-RNA. At the opposite Sepideh Nasimzadeh et al. investigate the presence of occult HCV in beta-thalassemia patients, the plasma and PBMCs were collected from 90 beta-thalassemia patients. They used gene sequence which is a sensitive and accurate method than transcription-mediated amplification (TMA) test performed by standardized quantitative real-time PCR [26]. This finding may promote the hypothesis of OCI-related cryptogenic hepatitis, in which elevated liver enzymes may be a consequence of the persistence of HCV in a low replicative state in liver cells, lymphoid tissue (PBMC) or both. This is in agreement with the findings of Castillo et al. who described the presence of HCV RNA in liver tissue samples from 57 out of 100 patients who were negative for HCV antibodies and HCV RNA but had elevated liver enzyme levels [30].

Additionally, in a recent interesting study by Elmasry et al. [31] 134 patients with recurrent HCV infection following liver transplantation were recruited and treated with DAAAs from 2014 through 2016. Out of the 129 patients who achieved SVR, the authors found that in more than 10% (no = 14) of the patients, the serum levels of
aminotransferases did not normalize during or after DAA therapy. Of those 14 patients, nine were assessed for occult HCV infection by reverse transcription quantitative PCR of samples obtained from both liver tissue and PBMCs. Their results revealed that 55% of those nine patients \((n = 5)\) had occult infections (three in liver tissue only, one in PBMCs only and one in both liver tissue and PBMCs), with the detection of the negative strand of the viral genome, indicating viral replication. Their findings are in agreement with ours, pointing to the presence of an underlying occult HCV infection in some patients as a possible cause for abnormal levels of serum aminotransferases in spite of achieving SVR 12 weeks after the end of DAA treatment.

However, an OCI can be present in the absence of elevated liver enzyme levels, as evidenced by Pham et al. [14], who reported OCIs in anti-HCV-positive patients who recovered after a self-limited (untreated) episode of hepatitis C and achieved SVR after interferon (IFN)-based treatment with normal liver enzyme levels.

Using the Cox proportional hazard model, we found a significant relationship between the presence of liver cirrhosis and the risk of developing an OCI \((HR; 5.828; 95\% CI: 1.3–26.1; P < 0.02)\). Similar data were reported by Rahman et al. [32], who concluded that late relapses can occur during long-term follow-up after SVR following IFN-based therapy. Importantly, they found that this occurred more often in patients with cirrhosis.

Similarly, Sood et al. [33] reported approximately 100 patients who achieved SVR and were followed for durations ranging from 6 months to 8 years. Eight of those 100 patients (8%) developed late recurrence. Late relapses were more frequent in patients with cirrhosis \((5/28 [18\%])\) than in those without cirrhosis \((3/72 [4\%]); P = 0.037)\).

The pretreatment viral load, the treatment type and the treatment duration were not associated with the persistence of the virus in the PBMCs.

Although the relevance of HCV-RNA detection in PBMCs and/or the liver tissues in the absence of serum RNA positivity is currently poorly understood, the ability of the virus to replicate in these extrahepatic sites with the possible transmission risk to other tissues or other persons means that the awareness of OCI in clinical settings needs to be raised [34].

The significance of the persistence of HCV RNA in PBMCs in patients treated with DAAs who have achieved a SVR remains to be clarified. It is not clear if this finding may reflect an ongoing declining process of the virus inside tissues or whether it may represent a genuine permanent persistence of the virus inside the PBMCs with later relapse and/or the induction of complications. The finding of a very low virus level \((less\ than\ 1000\ u/ml)\) in PBMCs in all 20 patients with OCIs may favor the assumption of a declining process. However, the HCV RNA detected in the serum of one of our patients 6 months after SVR may support the other possibility, pointing to a real problem posed by the long-term persistence of the virus in this group of patients. This may necessitate a long-term follow-up study investigating the possible long-standing existence of HCV RNA in PBMCs in patients reported to have OCIs.

An important marker in HCV patients is the serum levels of kappa and lambda free light chains (FLC) of chronic HCV patients which means HCV infects B-lymphocytes, provokes cellular dysfunction and causes lymphoproliferative diseases. Persistence of viral antigenic stimulation in occult hepatitis c patient leads to worsening of progression of HCV infection to lymphoproliferative and/or autoimmune diseases [35]. Detection of FLC in sera of OCI patients can inform us about the disease progression and induction of complication. FLC levels can be considered good biomarkers for identifying chronic HCV infection and its extrahepatic manifestation [36]. So we can compare the level of this marker between positive and negative HCV-RNA after they receive the DDA treatment in our future studies.

OCI remains a significant problem, even with highly effective DAAs, and it may play a major role in late relapse, cryptogenic hepatitis and other extrahepatic diseases. OCI in our study was significantly associated with elevated posttreatment serum transaminase levels. Liver cirrhosis is a significant risk factor for the occurrence of OCI following SVR. Ultimately, long-term studies to confirm the durability of an SVR after the use of interferon-free DAA regimens need to be conducted.

Acknowledgements The authors acknowledge Dr. Amani Mohammed for performing the statistical analysis in this study.

Authors’ contributions MK and YZ designed the study. They shared responsibility for patient recruitment and follow-up with ES, EA and AAAEF. MF and MK shared responsibility for entering the data, interpreting the results, reviewing the literature and writing the manuscript. HMM performed the laboratory investigations. NMA performed the radiological investigations. All authors revised and approved the final draft of the manuscript.

Funding Open access funding provided by The Science, Technology & The authors did not receive support from any organization for the submitted work.

Availability of data and material The datasets generated during and/or analyzed in the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Ethical approval The study protocol was approved by the Institutional Research Board of the Minia Faculty of Medicine in Egypt.
Informed consent  The study was conducted in accordance with the ethical guidelines in the 1975 Helsinki declaration. Informed written consents were taken from all the patients before participation in this study.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Vidimliski PD, Nikolov I, Geshkovska NM, Dimovsk A, Rosta... 4.254/vjh/v11.i6.67 (PMID: 21160967).
2. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir... 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

2. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir...
3. Baré P. Hepatitis C virus and peripheral blood mononuclear...
4. Cavaleiro ND, Filgueiras TC, Melo CE, et al. Detection of HCV...
5. Wang Y, Rao H, Chi X, et al. Detection of residual HCV-RNA in...
6. Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA,...
7. El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, El-saed K, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus2017s model of care. J Viral Hepat. 2017;24(4):262–7. https://doi.org/10.1111/jvhe.12668 (PMID: 28145032).
8. Tschochatzis EA, Bosovic J, Burroughs AK. Liver cirrhosis. Lancet Lond Engl. 2014;383(9930):1749–61. https://doi.org/10.1016/S0140-6736(13)62121-2 (PMID: 24299977).
9. Afshal NH. Fibro scan (Transient Elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol. 2012;8(9):605–7 (PMID: 23483859).
10. Smalley KJ, Knerr AN, Kendrick ZV, Collier JA, Owen OE. reassessment of body mass indices. Am J Clin Nutr. 1990;52(3):405–8. https://doi.org/10.1093/ajcn/52.3.405 (PMID: 2393001).
11. Nishida C, Ko GT, Kumanyika S. Body fat distribution and non-communicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr. 2010;64(1):2–5. https://doi.org/10.1038/ejcn.2009.139.
12. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993;15(3):532–4 (PMID: 7692896).
13. Lohr HF, Goergen B, Büschenfelde KH, Gerken G. HCV replication in mononuclear cells stimulates anti-HCV-secretory B cells and reflects nonresponsiveness to interferon-α. J Med Virol. 1995;46:314–20. https://doi.org/10.1002/jmv.1890460045.
14. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78(11):5867–74. https://doi.org/10.1128/JVI.78.11.5867-5874.2004 (PMID: 15140984).
15. Pham TN, King D, MacParland SA, McGrath JS, Reddy SB, Bursey FR, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134(3):812–22. https://doi.org/10.1053/j.gastro.2007.12.011 (PMID: 18243182).
16. Marco LD, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D, et al. Occult HCV infection: an unexpected finding in a population unscreened for hepatic disease. PLoS ONE. 2009;4(12):e8128. https://doi.org/10.1371/journal.pone.0008128 (PMID: 199956542PMID: PMC2780719).
17. Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM. Prevalence of occult hepatitis C virus in Egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat. 2012;2012:e429784. https://doi.org/10.1155/2012/429784.
18. Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol. 2012;18(23):2887–94. https://doi.org/10.3748/wjg.v18.23.2887 (PMID: 22736911).
19. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int. 2011;31:1519–24. https://doi.org/10.1111/j.1478-3231.2011.02613.x.
20. Haydon GH, Jarvis LM, Blair CS, Simmonds P, et al. Clinical significance of intrathecal hepatitis C virus levels in patients with chronic HCV infection. Gut. 1998;42(4):570–5. https://doi.org/10.1136/gut.42.4.570.
21. Sugiyasu Y, Yuki N, Nagaoka T, Yamashiro M, Kawahara K, Iyoda K, et al. Histological improvement of chronic liver disease after spontaneous serum hepatitis C virus clearance. J Med Virol. 2003;69(1):41–9. https://doi.org/10.1002/jmv.10250 (PMID: 12436476).
22. Bernardin F, Toulier L, Walsh I, Williams JD, Busch M, Delwart E, et al. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology. 2008;47(5):1446–52. https://doi.org/10.1002/hep.22184 (PMID: 18220272).
23. Carreño V, Pardo M, Lópezm-Acorojo JM, Itigo ER, Bartolomé J, Castillo I, et al. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA–negative patients with normal alanine aminotransferase levels. J Infect Dis. 2006;194(1):53–60. https://doi.org/10.1086/504692 (PMID: 16741882).
24. Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int. 2010;30(4):502–11. https://doi.org/10.1111/j.1478-3231.2009.02193.x (PMID: 20070513).
25. Pınarbaşi B, Bozaci M, Akyu F, Badur S, Demir K, Bessik F. The presence of HCVRNA in the peripheral blood mononuclear cells of the individuals with isolated anti HCV positivity: is HCV
26. Nasimzadeh S, Azaran A, Jalilian S, Makvandi M, Seyedian SS, Mehr FJ. Prevalence of occult hepatitis C virus infection in beta thalassemia major patients in Ahvaz, Iran. Arch Virol. 2021;166:2703–10. https://doi.org/10.1007/s00705-021-01526-

27. Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multicenter study. Infect Drug Resist. 2019;12:273–9. https://doi.org/10.2147/IDR.S181638 (PMID: 30774394).

28. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729–38. https://doi.org/10.1002/hep.22694 (PMCID: PMC2731713).

29. Halfon P, Bourlière M, Ouzan D, Sène D, Saadoun D, Khiri H, Pénaranda G, et al. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol. 2008;46(6):2106–8. https://doi.org/10.1128/JCM.00345-08 (PMID: 18448695).

30. Pawełczyk A, Kubisa N, Jabłońska J, Bukowska-Ośko I, Cortes KC, Fic M, et al. Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+. Virol J. 2013;10(1):1–6. https://doi.org/10.1186/1743-422X-10-346 (PMID: 24279719).

31. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Ibígo E, Lucas SD, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189(1):7–14. https://doi.org/10.1086/380202 (PMID: 14702147).

32. Elmasry S, Wadhwa S, Bang BR, Cook L, Chopra S, Kanel G, et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology. 2017;152(3):550–3. https://doi.org/10.1053/j.gastro.2016.11.002 (PMID: 27838287).

33. Rahman MZ, Ahmed DS, Masud H, Parveen S, Rahman MA, Chowdhury MS, et al. Sustained virological response after treatment in patients with chronic hepatitis C infection—a five year follow up. Bangladesh Med Res Counc Bull. 2013;39(1):11–3. https://doi.org/10.3329/bmrcb.v39i1.15791 (PMID: 23923405).

34. Sood A, Midha V, Mehta V, Sharma S, Mittal R, Thara A, et al. How sustained is sustained viral response in patients with hepatitis C virus infection? Indian J Gastroenterol. 2010;29(3):112–5 (PMID: 20803820).

35. Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21(1):15–9 (PMID: 23596274).

36. Oliveira IS, Cabral MS, Jesus LS, Paraná R, Atta AM, Luiza MB, et al. Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia. Braz J Infect Dis. 2014;18:638–42. https://doi.org/10.1016/j.bjid.2014.07.007.

37. Gulli F, Marino M, Napodano C, Gasbarrini A, et al. Biomarkers in HCV-related mixed cryoglobulinemia patients with non-Hodgkin lymphoma. Eur Rev Med Pharmacol Sci. 2020;24:8067–74. https://doi.org/10.26355/eurrev_202008_22490.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.